Evidence map›Paper›PMID 41360730›Full record

ArticleBritish journal of haematology2026

Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.

Sandra Ortega-Francisco, Maria Teresa Prudente de Aquino, Corinna La Rosa, Flavia Chiuppesi, Miguel-Angel Gutierrez, Jacqueline Miller, Jing Li, Jada Mack-Onyeike, Yifei Zhou, Qiao Zhou and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Sandra Ortega-FranciscoDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Maria Teresa Prudente de AquinoDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Corinna La RosaDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Flavia ChiuppesiDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Miguel-Angel GutierrezDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Jacqueline MillerDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Jing LiDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Jada Mack-OnyeikeDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Yifei ZhouDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Qiao ZhouDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Teodora KaltchevaDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Angela PattersonDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Shannon DempseyDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Sandra ThomasClinical Trials Office, City of Hope National Medical Center, Duarte, California, USA.
Katrin TiemannClinical Trials Office, City of Hope National Medical Center, Duarte, California, USA.
Dongyun YangDivision of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA.
Wasima RidaIndependent Biostatistics Consultant, Arlington, Virginia, USA.ORCID https://orcid.org/0000-0001-7671-7305
Felix WussowDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Kelly McKeeGeoVax, Smyrna, Georgia, USA.
Randy TaplitzDepartment of Medicine, City of Hope National Medical Center, Duarte, California, USA.
Erica RaidenGeoVax, Smyrna, Georgia, USA.
Tanya SiddiqiDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Steven RosenDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Don J DiamondDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Alexey DanilovDepartment of Hematology and HCT, Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA.

Funding

Briskin FoundationGeoVax, Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic lymphocytic leukaemiaCOVID‐19 vaccineshumoral responseneutralizing antibodiesSARS‐CoV‐2T cells

Identifiers

PMID41360730
PMCPMC12916199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.